EBS stock icon

Emergent Biosolutions
EBS

$6.89
1.77%
 

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Employees: 1,600

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

112% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $528K

7% less capital invested

Capital invested by funds: $98.2M [Q4 2023] → $91.1M (-$7.07M) [Q1 2024]

10.04% less ownership

Funds ownership: 78.84% [Q4 2023] → 68.8% (-10.04%) [Q1 2024]

11% less funds holding

Funds holding: 133 [Q4 2023] → 119 (-14) [Q1 2024]

37% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 46

41% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 34

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
27%
downside
Avg. target
$6.80
1%
downside
High target
$8
16%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Benchmark
Robert Wasserman
16%upside
$8
Buy
Reiterated
24 Jun 2024
Benchmark
Robert Wasserman
16%upside
$8
Buy
Reiterated
21 Jun 2024
Benchmark
Robert Wasserman
16%upside
$8
Buy
Maintained
20 Jun 2024
Benchmark
Robert Wasserman
27%downside
$5
Buy
Reiterated
11 Apr 2024
Benchmark
Robert Wasserman
27%downside
$5
Buy
Upgraded
7 Mar 2024

Financial journalist opinion